Lenalidomid 123-Acurae Pharma

Lenalidomide, the active ingredient in Lenalidomid 123-Acurae Pharma, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patients.

GNH USA supplies Lenalidomid 123-Acurae Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, acting on abnormal plasma cells and dysplastic marrow clones. - Multiple Myeloma: reduces disease progression and improves survival in eligible patients. - Myelodysplastic Syndromes with del(5q): corrects ineffective hematopoiesis and decreases transfusion dependence. - Mantle Cell Lymphoma: contributes to disease control when combined with other therapies.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate gastrointestinal upset.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Secondary primary malignancies: emergence of new cancers. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant parameters. - Pregnancy: contraindicated; ensure effective contraception for both patient and partner. - Thrombosis risk: assess history and consider prophylactic anticoagulation when appropriate. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust dosing based on renal function assessment. - Store at room temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Concurrent teratogenic agents: increase risk of fetal harm.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): monitor for enhanced bleeding. - Live vaccines: avoid due to potential reduced immune response. - NSAIDs: watch for renal function changes, especially in compromised patients.